Curidium is developing diagnostic tools that can be used to assess how individual patients will respond to treatments. Homomatrix is a technology that can identify specific patient subgroups. This can help doctors to prescribe the most appropriate treatment to a patient, which is known as personalised medicine. The main focus is central nervous system (CNS) ailments but the same diagnostics platform could be used as a basis for other medical areas. Curidium was established in 2001 and it reversed into Cielo Holdings in July 2006. On 8 March 2008, 30 shares were consoldiated in one new share.